Status:
COMPLETED
Procalcitonin Monitoring Sepsis Study
Lead Sponsor:
Brahms AG
Conditions:
Severe Sepsis
Septic Shock
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult patients (i.e. \>18 years of age) diagnosed with severe sepsis or septic shock as defined in Appendix 1, who are already in the ICU or come from the ED, other wards or directly from out of hospital
- Blood sample collection within 12 hours after diagnosis "severe sepsis or septic shock"No prior enrollment into this study
- Written informed consent
Exclusion
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
858 Patients enrolled
Trial Details
Trial ID
NCT01523717
Start Date
December 1 2011
End Date
March 1 2014
Last Update
March 17 2015
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Davis Health System
Sacramento, California, United States, 95817
2
Northwestern University
Chicago, Illinois, United States, 60611
3
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
4
Saint Vincent Hospital
Worcester, Massachusetts, United States, 01608